Schizophrenia & Psychosis
Search All News
Dr. Joshua Kantrowitz discusses a recent trial of CVN058, a drug that may reduce cognitive impairments in individuals with schizophrenia.
Columbia researchers have found a potential neurobiological mechanism for hallucinations and delusions that fits within the hierarchical model of psychosis and can explain their clinical presentation
- August 28, 2019
Dr. Gary Brucato, the Center of Prevention and Evaluation's Assistant Director, breaks down some of the early warning signs and symptoms of possible emergent psychotic illness.
Source:Psychiatry & Behavioral Health Learning NetworkAugust 14, 2019
This study “adds to a growing literature of using electrophysiological outcomes, including mismatch negativity as predictive biomarkers,” commented Dr. Joshua Kantrowitz.
- April 15, 2019
Columbia Psychiatrists suggest that researchers, pharmaceutical companies, and the FDA reconsider placebo-controlled, relapse prevention studies in schizophrenia.
Source:JAMAApril 10, 2019
Dr. Jeffrey Lieberman and colleagues conclude that the time has come to cease the use of placebo in relapse prevention studies and encourage the use of active comparators.
- March 21, 2019
A new study from Columbia University and New York State Psychiatric Institute offers insight into the development of delusions, which could lead to better treatments for people with psychosis.
Source:MD ALERTFebruary 28, 2019
"I expect that clinicians will change their practices by prescribing fewer benzodiazepines and more antidepressants for people with schizophrenia," Dr. T. Scott Stroup said.
Source:NewsDayFebruary 23, 2019
Schizophrenia and other psychotic disorders affect each person differently and vary in severity, said Dr. Lisa Dixon.
Source:HealioFebruary 21, 2019
“The effectiveness of combinations of antipsychotic medications remains unclear; reviews of this treatment strategy agree on the need for further investigation,” Dr. T. Scott Stroup and team wrote.